Source: http://www.businessweekly.co.uk/news/academia-research/cresset-three-way-uk-china-drug-design-alliance
By Kate Sweeney

Cambridge-based Cresset, which provides software and contract research services for small molecule discovery and design, has signed a three-way strategic UK-China agreement to speed up drug design.

Dr David Bardsley, Cresset’s commercial director, visited the School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou to sign a strategic co-operation agreement for drug design technology, developed within the Research Centre for Drug Discovery (RCDD).

This visit was in response to an invitation from Professor Jun Xu, RCDD, and was hosted by Wenhao Hu, dean of the School, and Huichang Bi, vice-dean of the School for International Development.

A further agreement was signed between Dr Bardsley and DeKang Zhang, chairman, iPrecison Medicine Technology Inc., whereby Cresset will promote iPrecision software and technology globally.

This agreement follows the transfer of 10 drug design software patents from RCDD to iPrecision last year.

Dr Bardsley said: “This British-Chinese three-way agreement brings together expertise and innovation in development of technologies for computational molecule design. I look forward to working with each organisation to establish global distribution channels.”

 PHOTOGRAPH: Back row (left to right) – Huichang Bi, Professor Jun Xu, DeKang Zhang, Zhishu Huang. Front – Wenhao Hu and Dr David Bardsley